Today: 29 April 2026
Browse Category

NASDAQ:PEN 15 January 2026 - 30 January 2026

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific stock price climbs as Penumbra deal stays in focus ahead of Feb. 4 earnings

Boston Scientific shares rose 1.7% to $93.87 Friday afternoon, outpacing a broader market decline. The move comes ahead of the company’s Feb. 4 earnings report and conference call, its first since announcing a $14.5 billion deal to acquire Penumbra. Investors are watching for details on the acquisition’s impact and the 2026 outlook.
30 January 2026
···
Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific (BSX) stock falls again as traders digest $14.5 billion Penumbra buy

Boston Scientific shares fell 1.8% to $88.44 Friday after its $14.5 billion deal to buy Penumbra, while Penumbra rose 0.3% to $351.62. Boston will fund most of the purchase with cash and new debt, expecting a $0.06–$0.08 hit to adjusted EPS in the first year. Penumbra shareholders can choose cash or Boston stock. Deal filings and Boston’s earnings call are set for February 4.
16 January 2026
··
Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra stock pops after Boston Scientific’s $14.5 billion buyout — what PEN investors watch next

Penumbra shares jumped 11.8% to $350.49 in after-hours trading Thursday after Boston Scientific announced a $14.5 billion cash-and-stock acquisition valuing Penumbra at $374 per share. The deal requires Penumbra shareholder approval and antitrust clearance. Penumbra posted preliminary Q4 revenue growth of over 21% year-over-year. Traders focused on the deal spread and closing risks.
15 January 2026
··
Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific’s $14.5B Penumbra buy: $374-a-share deal lifts PEN stock before the open

Boston Scientific will acquire Penumbra for about $14.5 billion, offering $374 per share in cash and stock. Penumbra shares rose more than 13% premarket, with the bid representing a 19.3% premium to the previous close. The deal expands Boston Scientific’s reach in catheter-based clot removal and neurovascular devices. Penumbra CEO Adam Elsesser will join Boston Scientific’s board.
15 January 2026
··

Stock Market Today

  • April FOMC US Index Levels Update: Dow Jones, Nasdaq, S&P 500
    April 29, 2026, 1:36 PM EDT. Stocks face volatility ahead of key earnings reports from tech giants Meta, Alphabet, Amazon, and Microsoft after market close. Investors seek signs that massive infrastructure spending and AI investments, fueled by trillions of dollars, are generating expected returns. This scrutiny recalls the 2025 AI/Tech crash triggered by unmet high expectations. Meanwhile, geopolitical tensions persist as the US-Iran standoff affects the Strait of Hormuz, pushing oil prices above $105 per barrel. Elevated crude prices raise concerns over inflation and market stability. The market waits on April FOMC signals and intraday performance metrics for the Dow Jones, Nasdaq, and S&P 500 to gauge risk appetite amid these economic and geopolitical pressures.

Latest article

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

Dow Jones Today: Why the Blue-Chip Index Is Sliding Before Powell, Big Tech and the Oil Shock

29 April 2026
The Dow Jones Industrial Average dropped 320 points, or 0.65%, to 48,821.82 Wednesday afternoon, heading for a fifth straight loss as investors awaited the Federal Reserve’s rate decision and major tech earnings. Brent crude surged 7.14% to $119.20 after reports of a possible extended Iran blockade. Boeing and Goldman Sachs weighed on the Dow, while Amazon rose and Microsoft slipped in midday trading.
General Dynamics Corporation Stock Jumps After Submarine Orders, Gulfstream Jets Lift 2026 Outlook

General Dynamics Corporation Stock Jumps After Submarine Orders, Gulfstream Jets Lift 2026 Outlook

29 April 2026
General Dynamics raised its 2026 profit outlook after first-quarter earnings and revenue topped estimates, sending shares up 10.9% to $347.72. The company reported $1.4 billion in operating earnings and $13.5 billion in revenue, with Marine Systems revenue up 21% on submarine programs. Orders reached $26.6 billion, pushing backlog to $130.8 billion. General Dynamics ended the quarter with $3.7 billion in cash.
Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

Teva Stock Jumps As Branded Drugs Start Carrying The Old Generics Giant

29 April 2026
Teva reported first-quarter adjusted earnings of 53 cents per share on $3.98 billion revenue, beating estimates as sales of Austedo, Ajovy, and Uzedy climbed. Shares jumped 11% in New York trading. The company agreed to buy Emalex Biosciences for $700 million upfront, adding a late-stage Tourette syndrome drug candidate. Global generics revenue fell 16% amid increased competition.
Go toTop